Cochlear Implantation

CI Basics - Bionic Ear 101

• Definition: A cochlear implant (CI) is a surgically implanted electronic device. It provides a sense of sound to individuals with severe-to-profound sensorineural hearing loss (SNHL).
• Mechanism: CIs bypass damaged cochlear hair cells. They directly stimulate auditory nerve fibers (spiral ganglion cells) using electrical impulses.
• Key Components:
  • External: Microphone, speech processor, transmitting coil.
  • Internal: Receiver-stimulator (implanted subcutaneously), electrode array (inserted into scala tympani of cochlea).
• Signal Path: Sound → Microphone → Speech Processor → Transmitter (external) → Receiver (internal) → Electrode Array → Auditory Nerve → Brain.

⭐ Cochlear implants directly stimulate spiral ganglion cells (auditory nerve fibers) within the cochlea.

CI Candidacy - Green Light Ears

CI is for those with significant hearing loss not adequately helped by hearing aids. "Green light" indicates strong candidacy.

• Key Audiological Thresholds:
  • Adults: Bilateral severe-profound SNHL (PTA >70 dB HL). Speech recognition ≤50% (implanted ear) or ≤60% (best-aided).
  • Children (12-24m): Bilateral profound SNHL (PTA ≥90 dB HL). Limited auditory progress with HAs.
  • Children (>24m): Bilateral severe-profound SNHL. Speech scores (e.g., MLNT/LNT) ≤30%.
• Essential Anatomy: Patent cochlear duct, identifiable auditory nerve (CN VIII).
• Overall Status: No active middle ear disease, fit for surgery, strong motivation, and realistic expectations.

⭐ For pre-lingually deafened children, implantation before 2 years of age (ideally <18 months) yields best speech/language outcomes.

CI Workup & Surgery - Journey to Sound

Comprehensive Workup:

• Audiological: PTA, Speech Discrimination Score (SDS) < 50% (aided), OAE, ABR, EABR. Promontory stimulation test (PST) for nerve viability.
• Radiological: HRCT Temporal Bone (cochlear patency, ossification, anomalies), MRI (CN VIII integrity, labyrinthine fluid).

  ⭐ HRCT is crucial to assess cochlear duct patency (e.g., for cochlear aplasia/hypoplasia) & identify anomalies like Mondini dysplasia.

• Medical fitness, psychological assessment, realistic expectations.
• Vaccinations: Pneumococcal, H. influenzae type b, Meningococcal.

Surgical Pathway:

• Facial Recess: Bounded by Chorda tympani (lat), Facial N. (med), Fossa incudis (sup). 📌 "CN VII sandwich"
• Post-op: Auditory rehabilitation, regular mapping.

Post-CI & Outcomes - Switched On Life

• Switch-on: Typically 2-4 weeks post-operatively.
• Mapping (Programming): Regular audiologist sessions to program T-levels (threshold) & C/M-levels (comfortable/maximum) for each electrode.
• Auditory Rehabilitation: Intensive therapy (audiologist, Speech Language Pathologist - SLP) is KEY. Focus on:
  • Listening skills development.
  • Speech discrimination & production.
• Outcomes:
  • Significant ↑ in speech perception (open-set & closed-set scores).
  • Improved hearing in noise & sound localization (especially with bilateral CIs).
  • Enhanced Quality of Life (QoL).
• Favorable Prognostic Factors:
  • Younger age at implantation (esp. pre-lingual <2 years).
  • Shorter duration of profound deafness.
  • Consistent device use & commitment to rehabilitation.
  • Good cochlear nerve status & cognitive abilities.
• Long-term Considerations: Monitor for device malfunction/failure, electrode migration; potential for reimplantation.
• 
• ⭐ > For prelingually deaf children, implantation before 18 months of age is associated with the best prognosis for developing age-appropriate speech and language skills.

High‑Yield Points - ⚡ Biggest Takeaways

• Indicated for bilateral severe-to-profound SNHL with poor hearing aid benefit.
• Requires patent cochlea (especially scala tympani) and functional auditory nerve.
• Electrode array inserted into scala tympani, commonly via round window or cochleostomy.
• Post-operative mapping (NRT, ART) and intensive auditory-verbal therapy are crucial.
• Minimum age typically 12 months; earlier if post-meningitic ossification risk.
• Key contraindications: Michel aplasia, auditory nerve aplasia, active otitis media.